Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10
New York, Jan 15, 2026, 12:06 — Regular session Eli Lilly and Company shares dropped 4.7% to $1,022.50 on Thursday after Reuters reported that internal documents revealed U.S. regulators delayed a decision on the drugmaker’s weight-loss pill until April 10. A Lilly spokesperson said approval could still come in the second quarter, aligning with current FDA guidance. Holly Fernandez Lynch, a health-policy professor at the University of Pennsylvania, commented on the FDA’s cautious stance, saying, “Hold on, we’re not actually sure this product should be allowed on the market,” highlighting the agency’s readiness to slow fast-tracked reviews.